Vericel Corporation Common Stock (VCEL)
Stock · NASDAQ · Health Care
$40.11as of 10/16/2026
Price chart
Active signals
VCEL Signal Track Record
How signals performed across all stocks →What VCEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +2.7% | 53% | September 18, 2026 |
| Bollinger Band Breakout | 23 | -2.0% | 39% | June 26, 2026 |
| Bollinger Band Breakdown | 20 | +4.2% | 65% | August 20, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -3.7% | 43% | September 10, 2026 |
| Any 20-session window (baseline) | +1.1% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 398
- Website
- vcel.com/
Fundamentals
- 1-day range
- $39.81$41.55
- Market cap
- $2.29B
- P/E (trailing)
- 85.09
- P/E (forward)
- 47.19
- EPS (trailing)
- $0.42
- Dividend yield
- —
- Beta
- 1.06
- Avg. volume
- 510.6K
How Vericel Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Vericel Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
- RVMDWRevolution Medicines Inc. Warrant$8.4▼ 13.98%Market cap $2.25BP/E —$0.2311$13.44
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
| RVMDW Revolution Medicines Inc. Warrant | $2.25B | — | $8.4 | ▼ 13.98% | $0.2311$13.44 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Truist Securities Maintains Buy on Vericel, Lowers Price Target to $52benzinga · 10/14/2026
- Vericel (VCEL) Stock Looks Fully Priced After A 31% GainYahoo · 9/26/2026
- Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Vericel: MACI And Regenerative Knee CartilageSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- MCLAUGHLIN KEVIN F · August 12, 2026 · Option Exercise7.0K @ $13.05
- MCLAUGHLIN KEVIN F · August 12, 2026 · Sale7.0K @ $44.53
- Halpin Michael · August 3, 2026 · Option Exercise10.0K @ $16.66
- Halpin Michael · August 3, 2026 · Sale10.0K @ $46.84
- SIEGAL JONATHAN · July 30, 2026 · Option Exercise500 @ $29.82
- SIEGAL JONATHAN · July 30, 2026 · Option Exercise2.5K @ $29.82
- SIEGAL JONATHAN · July 30, 2026 · Option Exercise1.5K @ $34.9
- SIEGAL JONATHAN · July 30, 2026 · Sale500 @ $48.9
- SIEGAL JONATHAN · July 30, 2026 · Sale2.5K @ $48.9
- SIEGAL JONATHAN · July 30, 2026 · Sale1.5K @ $48.9
- Flynn Sean C. · June 18, 2026 · Option Exercise15.0K @ $16.25
- Flynn Sean C. · June 18, 2026 · Sale15.0K @ $40.21
- Halpin Michael · June 18, 2026 · Option Exercise10.0K @ $16.66
- Halpin Michael · June 18, 2026 · Sale10.0K @ $40.24
- Hopper Jonathan Mark · June 2, 2026 · Option Exercise4.4K @ $16.66
Institutional Ownership
March 31, 2026
- Total shares held
- 55.60M
- Total value held
- $1.71B
- Institutional holders
- 271
- Unknown7.77M
- Unknown3.15M
- Unknown2.55M
- Unknown2.46M
- Unknown2.23M
- Unknown1.96M
- Unknown1.83M
- Unknown1.72M
- Unknown1.65M
- Unknown1.62M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Truist lowers Vericel price target to $52
Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.
Truist lowers Vericel price target to $52. Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.